Projects per year
Fingerprint
Dive into the research topics where Asher A Chanan Khan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Therapeutic implication of CD38 in CLL
Chanan-khan, A. A. A., Chini, E. E. N., Chanan Khan, A. A. & Chini, E. N.
9/4/19 → 8/31/24
Project: Research project
-
VACCINE FOR PATIENTS WITH NON HODGKINS LYMPHOMA
Chanan Khan, A. A. & Bernstein, S. H.
9/18/00 → 9/1/03
Project: Research project
-
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia
Parrondo, R. D., Dutta, N., LaPlant, B. R., Elliott, J., Fernandez, A., Zimmerman, A., Cicco, G., Han, B., Heslop, K., Chapin, D., Sher, T., Roy, V., Rasheed, A., Das, S., Chanan-Khan, A. A., Paulus, A. & Ailawadhi, S., 2024, (Accepted/In press) In: British journal of haematology.Research output: Contribution to journal › Article › peer-review
-
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
Alhaj Moustafa, M., Parrondo, R., Abdulazeez, M. F., Roy, V., Sher, T., Alegria, V. R., Warsame, R. M., Fonseca, R., Rasheed, A., Gonsalves, W. I., Kourelis, T., Kapoor, P., Buadi, F. K., Dingli, D., Hayman, S. R., Reeder, C. B., Chanan-Khan, A. A. & Ailawadhi, S., Jan 1 2024, In: Anti-cancer drugs. 35, 1, p. 63-69 7 p.Research output: Contribution to journal › Article › peer-review
-
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
Ailawadhi, S., Parrondo, R. D., Dutta, N., Han, B., Ciccio, G., Cherukuri, Y., Alegria, V. R., LaPlant, B. R., Roy, V., Sher, T., Edwards, B., Lanier, S., Manna, A., Heslop, K., Caulfield, T., Maldosevic, E., Storz, P., Manochakian, R., Asmann, Y., Chanan-Khan, A. A., & 1 others , Jan 2023, In: Cancers. 15, 2, 477.Research output: Contribution to journal › Article › peer-review
Open Access -
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
Seymour, J. F., Byrd, J. C., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Brown, J. R., Munir, T., Mato, A., Stilgenbauer, S., Bajwa, N., Miranda, P., Higgins, K., John, E., de Borja, M., Jurczak, W. & Woyach, J. A., Aug 24 2023, In: Blood. 142, 8, p. 687-699 13 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
Mondello, P., Paludo, J., Novak, J. P., Wenzl, K., Yang, Z. Z., Jalali, S., Krull, J. E., Braggio, E., Dasari, S., Manske, M. K., Abeykoon, J. A., Sarangi, V., Kapoor, P., Paulus, A., Reeder, C. B., Ailawadhi, S., Chanan-Khan, A. A., Kyle, R. A., Gertz, M. A., Novak, A. J., & 1 others , Mar 1 2023, In: Clinical Cancer Research. 29, 5, p. 957-970 14 p.Research output: Contribution to journal › Article › peer-review
Open Access